Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
ID: 351505Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351505

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-019.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the "Sustained Support for Informatics Technologies for Cancer Research and Management" funding opportunity, which aims to enhance and maintain established informatics resources critical to cancer research. This initiative seeks proposals that demonstrate the impact of informatics technologies on various aspects of cancer research, including biology, treatment, prevention, and health disparities, while requiring detailed plans for user engagement and resource evolution. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and for-profits, with applications due by November 15, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-019.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-CA-24-019-Full-Announcement.html
    RFA-CA-24-019.html
    The National Institutes of Health (NIH) is inviting submissions for a funding opportunity focused on sustaining informatics technologies relevant to cancer research through Cooperative Agreements (U24). This opportunity aims to support the continued operation and enhancement of established informatics resources integral to various areas of cancer research, including biology, treatment, prevention, and health disparities. Proposals must demonstrate the proven impact of the technology on cancer research, and include detailed plans for user support, engagement, and the resource’s evolution to meet emerging research needs. The budget is flexible but must reflect actual project requirements, with a maximum project duration of five years. Eligible applicants encompass a broad range of organizations including higher education institutions, nonprofits, and for-profits. Applications are due by November 15, 2024, and are subject to extensive review processes evaluating scientific merit, project significance, and investigator qualifications. This opportunity stresses the collaboration between researchers and NIH staff to promote relevant technological advancements in cancer research while addressing user community needs effectively.
    Similar Opportunities
    Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Advanced Development of Informatics Technologies for Cancer Research and Management" (RFA-CA-24-018). This initiative aims to support cooperative agreements that focus on the enhancement of emerging informatics technologies to improve data acquisition, management, analysis, and dissemination across the cancer research continuum. The program is particularly significant as it seeks to advance technologies that have shown initial viability but require further development to achieve a broader impact in cancer research, addressing critical health disparities and improving patient outcomes. NIH anticipates funding approximately four awards totaling $3.6 million for fiscal year 2025, with individual budgets capped at $600,000 per year over a five-year period. Applications are due by November 15, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)." This initiative aims to support the development of innovative informatics tools that enhance the acquisition, analysis, dissemination, and management of cancer-related data, focusing on areas such as biology, treatment, early detection, and health disparities. The program encourages collaboration with end-users to ensure the practical utility of the proposed technologies, with approximately $2.25 million available for 5-6 awards, each with a maximum budget of $300,000 per year for up to three years. Interested applicants should note that the application process opens on May 11, 2024, with a submission deadline of November 15, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the development of innovative informatics methods and algorithms aimed at enhancing cancer research and management through the R21 exploratory/developmental research grant. This initiative seeks applications that propose novel approaches to improve data acquisition, analysis, visualization, and interpretation across various aspects of cancer research, including biology, treatment, diagnosis, and health disparities. The NIH plans to fund approximately five awards totaling $1,020,000, with individual project budgets not exceeding $275,000 for a two-year period. Interested applicants must submit their proposals by November 15, 2024, and can find additional information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)" aimed at supporting exploratory research projects that develop innovative technologies to enhance the quality of biospecimens used in cancer research. The initiative focuses on addressing pre-analytical degradation of cancer-relevant biospecimens during collection, processing, and storage, with the goal of improving sample integrity and utility for downstream analyses. This funding is particularly significant for advancing research in cancer biology, early detection, and treatment, while also addressing health disparities. Grants of up to $150,000 are available, with applications opening on March 1, 2024, and a submission deadline of October 1, 2024. For more information, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-010.html.
    Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This grant aims to support exploratory research projects focused on the early-stage development of innovative technologies that enhance molecular and cellular analysis capabilities in cancer research, with an emphasis on technical innovation and addressing cancer health disparities. The total funding available is approximately $4.2 million, with individual grants of up to $150,000 per year for a maximum of three years. Applications will be accepted starting March 1, 2024, with a submission deadline of October 2, 2024. For more information, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-008.html.
    Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)." This initiative invites revision applications from currently funded NCI R01 research projects, encouraging applicants to enhance their original research by integrating innovative technologies developed through the NCI Innovative Molecular Analysis Technologies (IMAT) program. The goal is to foster interdisciplinary collaboration and accelerate scientific discovery in cancer research. Interested applicants can apply for grants of up to $150,000 annually for a maximum of two years, with applications accepted starting March 1, 2024, and a submission deadline of October 1, 2024. For further details, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-012.html.
    Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P30 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research," aimed at enhancing cancer research through innovative technologies. This initiative encourages currently funded NCI P30 Cancer Center Support Grants (CCSG) recipients to expand their research by integrating new technical approaches developed through the NCI's Innovative Molecular Analysis Technologies (IMAT) program. The program is designed to foster interdisciplinary collaboration and promote independent validation of emerging technologies, thereby accelerating scientific discovery in cancer research. Interested applicants can apply for up to $150,000 per year, with a total funding pool of approximately $600,000 available for up to three awards. Applications are due by 5 PM local time on October 2, 2024, and further inquiries can be directed to grantsinfo@nih.gov. For more details, visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-015.html.
    Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)." This initiative aims to support exploratory research projects that focus on developing and validating innovative technologies to enhance the quality of biospecimens used in cancer research, specifically addressing pre-analytical variations that can compromise sample integrity. The program is part of the Innovative Molecular Analysis Technologies (IMAT) initiative and seeks projects that demonstrate preliminary data supporting their feasibility, with a funding ceiling of $300,000 per year for up to three years. Applications are due by October 1, 2024, and interested applicants can find more information and guidance by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-011.html.
    Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting grant applications for the "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research" initiative, which is part of the Innovative Molecular Analysis Technologies (IMAT) Program. This funding opportunity aims to support exploratory research projects that address significant gaps in current cancer research methodologies, focusing on the development and validation of novel technologies that enhance the understanding and treatment of cancer, including early detection, screening, and addressing health disparities. Eligible applicants can request up to $300,000 annually for a project period not exceeding three years, with a total of approximately $4.3 million available for 10 anticipated awards in fiscal year 2025. Applications will be accepted starting March 1, 2024, with a submission deadline of October 2, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for revision applications aimed at incorporating novel technologies developed through the NCI Innovative Molecular Analysis Technologies (IMAT) program to accelerate cancer research. This initiative encourages currently funded NCI P50 specialized centers to expand upon their original research questions by integrating innovative tools and methods, thereby promoting interdisciplinary collaboration and enhancing the rigor of ongoing studies. With a funding ceiling of $150,000 per year and a total of approximately $600,000 anticipated to support three awards for fiscal year 2025, eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and foreign entities. Interested parties should submit their applications by October 1, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.